Figure 2.

Recommendations for future research and clinical applications in the CAR T-cell field. A. CAR T-cells should be administered in high doses and in a split-dosing manner for safety reasons; B. research should shift to detect tumor-specific antigens and invent more sensitive techniques to facilitate the interpretation of results; C. the CAR T-cell starting material should be defined in terms of composition of CAR T-cell subpopulations; D. anti-idiotypic antibodies should be developed and administered in potentially “cured” CLL patients who are under high risk of infections, to eradicate remaining CAR T-cells and restore B-cell aplasia; E. remission or cure? larger cohorts are needed to confirm the clinical status across other CLL patients, as well as other malignancies